First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalExpert Review of Anticancer Therapy
DOIs
Publication statusAccepted/In press - Jul 16 2016

Keywords

  • angiogenesis
  • bevacizumab
  • EGFR
  • erlotinib
  • NSCLC
  • TKI
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this